DWM
TRIL

Destination Wealth Management’s Trillium Therapeutics Inc. TRIL Stock Holding History

Destination Wealth Management’s Portfolio TRIL Stock Details TRIL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-16,361
Closed -$357K – 232
2015
Q2 		$357K Buy
+16,361
New +$373K 0.02% 190

Other funds holding TRIL

JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
PCA
Private Capital Advisors Darien, Connecticut $1.14B AUM 48.66% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
EAM
EverPoint Asset Management Stamford, Connecticut $5.38B AUM 21.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return

Destination Wealth Management's TRIL Position: Q3 2015 in Review

Destination Wealth Management sold out of Trillium Therapeutics Inc. (TRIL) in Q3 2015, closing a stake of 16,361 shares — an estimated $357K sold.

Destination Wealth Management first reported a position in TRIL in Q2 2015 and held it in 1 quarter. The position peaked at $357K in Q2 2015. 33 funds tracked by Wall St. Rank hold TRIL as of Q3 2015.

  • Destination Wealth Management reported no remaining Trillium Therapeutics Inc. position as of Q3 2015 after selling out during the quarter.
  • Destination Wealth Management sold 16,361 Trillium Therapeutics Inc. shares in Q3 2015, an estimated $357K.
  • Destination Wealth Management first reported a position in Trillium Therapeutics Inc. in Q2 2015 and held it in 1 quarter.
  • Destination Wealth Management's Trillium Therapeutics Inc. position peaked at $357K in Q2 2015.
  • 33 funds tracked by Wall St. Rank held Trillium Therapeutics Inc. as of Q3 2015.

Based on Destination Wealth Management's 13F filing for Q3 2015, filed 30 Oct 2015.